ABLYNX (OTCMKTS:ABLYF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “
Separately, Bank of America initiated coverage on shares of ABLYNX in a report on Friday, November 10th. They set a “buy” rating and a $26.00 target price for the company.
Shares of ABLYNX (OTCMKTS:ABLYF) remained flat at $$38.48 on Friday. ABLYNX has a 12 month low of $11.10 and a 12 month high of $50.00.
TRADEMARK VIOLATION NOTICE: “ABLYNX (ABLYF) Stock Rating Lowered by Zacks Investment Research” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://ledgergazette.com/2018/01/12/ablynx-ablyf-stock-rating-lowered-by-zacks-investment-research.html.
Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.
Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.